Sight Sciences (SGHT) Expected to Announce Quarterly Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Sight Sciences to announce earnings of ($0.15) per share and revenue of $21.6940 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.05). Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%.The business had revenue of $19.70 million for the quarter, compared to analysts’ expectations of $18.46 million. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $5.26 on Monday. The company has a current ratio of 5.86, a quick ratio of 5.48 and a debt-to-equity ratio of 0.68. The company has a market cap of $286.20 million, a PE ratio of -7.41 and a beta of 2.38. The company’s fifty day simple moving average is $5.11 and its 200-day simple moving average is $4.92. Sight Sciences has a 52 week low of $3.11 and a 52 week high of $9.24.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Citigroup increased their price target on Sight Sciences from $5.15 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Weiss Ratings cut Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Finally, UBS Group began coverage on Sight Sciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $7.00 target price for the company. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.75.

Insider Activity

In other Sight Sciences news, CEO Paul Badawi sold 28,684 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total value of $155,467.28. Following the completion of the transaction, the chief executive officer directly owned 6,122,472 shares of the company’s stock, valued at $33,183,798.24. This represents a 0.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James Rodberg sold 6,902 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $5.36, for a total value of $36,994.72. Following the sale, the chief financial officer owned 224,037 shares of the company’s stock, valued at $1,200,838.32. This represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 58,566 shares of company stock worth $318,827. 30.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sight Sciences

A number of institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in shares of Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after buying an additional 3,785 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new stake in shares of Sight Sciences in the 4th quarter worth about $81,000. Tower Research Capital LLC TRC lifted its position in shares of Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in Sight Sciences in the fourth quarter worth about $96,000. Finally, Kemnay Advisory Services Inc. bought a new stake in Sight Sciences in the fourth quarter valued at about $107,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.